Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099222 | 0.92 | FFAR4 (0.40) | FFAR4FFAR1MAOBPDE3BPDE3A | |
| SCHEMBL21052437 | 0.85 | ALB (0.42) | FFAR4FFAR1BRD4MAOBPDE3B | |
| SCHEMBL30231915 | 0.84 | BRD4 (0.61) | FFAR1BRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL21098799 | 0.84 | BRD4 (0.61) | FFAR1BRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL21098681 | 0.77 | RXRA (0.41) | FFAR4MAOBPDE3BPDE3AP2RY12 | |
| SCHEMBL21052000 | 0.77 | BRD4 (0.53) | FFAR1BRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL21098760 | 0.76 | KDM4E (0.41) | FFAR4FFAR1PDK2 | |
| SCHEMBL21098683 | 0.75 | MAOB (0.63) | BRD4MAOB | |
| SCHEMBL21098668 | 0.74 | PPARD (0.40) | FFAR4FFAR1MAOBMCL1 | |
| SCHEMBL22412334 | 0.74 | MAOB (0.51) | FFAR1BRD4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-24 | — | — | US | disclosed |
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-24 | — | — | US | disclosed |
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | KAT7, AADAC, HDAC7 | FFAR4 2768/4885FFAR1 3835/4885BRD4 819/4885 |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | AADAC, HDAC8, KAT8 | FFAR4 2895/4885FFAR1 3745/4885BRD4 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.